Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
BCAL Diagnostics Limited ( (AU:BDX) ) just unveiled an announcement.
BCAL Diagnostics reported progress on the national rollout of its Avantect pancreatic and ovarian blood tests, now available through Sonic Healthcare and Healius pathology networks, generating $88,000 in third-quarter revenue from 91 tests. A new digital platform has drawn strong interest from clinicians and patients, underscoring unmet demand for early cancer detection solutions.
The company has lodged an application with the Medical Services Advisory Committee seeking Medicare reimbursement for its pancreatic cancer test in at-risk individuals, a move that could support wider adoption and longer-term revenue growth. BCAL also completed development of its next-generation breast cancer test, BREASTESTplus 2.0, which broadens the eligible population to women over 30 across all breast densities, with a national launch planned for the first quarter of FY27.
Internal validation shows BREASTESTplus 2.0 can detect signals across early and later-stage breast cancers with high sensitivity and a strong negative predictive value, potentially enhancing its clinical utility. The company is bolstering clinical engagement through education portals, software integrations and key opinion leader support, while strengthening governance with the appointment of experienced healthcare technology executive Mark McConnell to its board.
Two scientific manuscripts on BREASTESTplus have been submitted for publication, which may help underpin clinical credibility and support market access efforts. These developments collectively signal a transition from development to early commercialisation for BCAL’s portfolio, with potential implications for revenue visibility and its positioning in the growing early cancer diagnostics market.
More about BCAL Diagnostics Limited
BCAL Diagnostics Limited is an Australian healthcare company focused on developing and commercialising blood-based tests for the early detection of cancers, including breast, pancreatic and ovarian cancers. The company targets both clinicians and patients through national pathology networks and digital platforms, aiming to expand access to non-invasive diagnostic tools.
Average Trading Volume: 199,594
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$31.34M
Learn more about BDX stock on TipRanks’ Stock Analysis page.